Antibody-drug conjugates, or ADCs, are a targeted way to treat cancer.
For over 35 years, ImmunoGen has been researching and developing ADCs designed to disrupt the progression of cancer. Because we believe life deserves fewer interruptions and more good days.
Baruj Benacerraf, head of the Sydney Farber Cancer Institute (now the Dana Farber Cancer Institute), was approached by a small group of investors with a vision: to create more effective, better tolerated anti-cancer therapies. Specifically, they wanted to find a way to leverage the targeting ability of antibodies to deliver toxic drug directly to cancer cells. Benacerraf went on to suggest that the investors start with a grant from which the Institute would work with dedicated scientists.
The rest, they say, is our history…